Sendogan, FurkanTuran, TurgayKeser, FerhatHancilar, TayfunAtis, GokhanYildirim, AsifAcil Tıp / Emergency Medicine2024-05-252024-05-25202302080-48062080-487310.5173/ceju.2023.1902-s2.0-85164591751https://doi.org/10.5173/ceju.2023.190https://hdl.handle.net/20.500.14517/1252Keser, Ferhat/0000-0002-2803-6481Introduction The aim of this study was to compare the long-term oncological results of patients with the diagnosis of prostate cancer who underwent open radical retropubic prostatectomy (RRP) and subse-quent adjuvant (ART) or salvage radiotherapy (SRT).Material and methods A total of 145 patients underwent open RRP for prostate cancer and subsequent ART or SRT postoperatively between 2010 and 2019. ART (n = 56) is defined as the group of patients with prostate-specific antigen (PSA) <0.2 ng/mL or with positive lymph nodes without PSA increase who re-ceived radiotherapy within the first 6 months of urinary continence. SRT (n = 89) is defined as the group of patients with PSA >0.2 ng/mL who received RT before PSA amounted to 0.5 ng/mL.Results Statistically no significant difference was found between groups in terms of age, prostate volume, final pathology Gleason scores, lymphadenectomy, duration of androgen deprivation therapy (ADT), time to relapse after radiotherapy, development of biochemical recurrence and disease progression. Extraprostatic extension, seminal vesicle invasion and surgical margin positivity were significantly higher in the ART group. No difference was found between the groups in terms of biochemical recurrence-free survival, while cancer-specific survival and overall survival rates were significantly higher in the SRT group.Conclusions It was found that cancer-specific and overall survival was better in the SRT group. It will be more appropriate to follow-up until the recurrence and then to perform SRT after the relapse in the postoperative period.eninfo:eu-repo/semantics/openAccessprostate cancerbiochemical recurrenceadjuvant radiotherapysalvage radiotherapyOncologic outcomes of postoperative adjuvant versus salvage radiotherapy in prostate cancerArticleQ3WOS:00096679840000137483851